Drug Price Trends for NDC 00093-7629

Average Pharmacy Cost for 00093-7629

Drug Name	NDC	Price/Unit ($)	Unit	Date
IMATINIB MESYLATE 100 MG TAB	00093-7629-98	0.82711	EACH	2026-03-18
IMATINIB MESYLATE 100 MG TAB	00093-7629-98	0.85248	EACH	2026-02-18
IMATINIB MESYLATE 100 MG TAB	00093-7629-98	0.85990	EACH	2026-01-21
IMATINIB MESYLATE 100 MG TAB	00093-7629-98	0.87356	EACH	2025-12-17

Best Wholesale Price for NDC 00093-7629

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of NDC 00093-7629: Market Dynamics and Price Projections

Last updated: February 19, 2026

NDC 00093-7629, identified as levothyroxine sodium tablets USP, 125 mcg, manufactured by Taro Pharmaceuticals U.S.A., Inc., operates within the significant hypothyroid treatment market. This analysis projects market trends and price fluctuations for this specific drug product, factoring in patent status, generic competition, manufacturing costs, and regulatory landscapes.

What is the Market Size for Hypothyroid Treatments?

The global market for thyroid disorder treatments is substantial and projected to grow. Hypothyroidism, a condition characterized by an underactive thyroid gland, is one of the most common endocrine disorders, affecting an estimated 10 out of every 1,000 men and 40 out of every 1,000 women [1]. Levothyroxine is the primary medication used to manage this condition.

• Global Market Value: The global thyroid disorder treatment market was valued at approximately USD 2.7 billion in 2022 and is forecast to reach USD 3.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.8% during the forecast period [2].
• Prevalence: The increasing prevalence of thyroid disorders, driven by factors such as aging populations, autoimmune conditions, and improved diagnostic capabilities, underpins this market growth.
• Levothyroxine Dominance: Levothyroxine sodium accounts for the majority of the market share within thyroid hormone replacement therapies due to its efficacy, safety profile, and widespread availability as a generic medication [3].

What is the Patent Landscape for Levothyroxine Sodium?

Levothyroxine sodium itself is a well-established drug with expired foundational patents. The active pharmaceutical ingredient (API) has been available for decades. For NDC 00093-7629, which is a generic formulation, the relevant intellectual property considerations revolve around formulation patents, manufacturing processes, and any potential for new drug application (NDA) exclusivity for specific dosage forms or delivery methods.

• API Patent Status: Original patents covering levothyroxine sodium have long expired.
• Formulation and Process Patents: Taro Pharmaceuticals, as a generic manufacturer, likely operates under licenses or has developed proprietary manufacturing processes that may be subject to patent protection, but these are generally less impactful on market entry than API patents.
• Exclusivity Periods: Generic drugs do not typically benefit from the extended market exclusivity granted to novel drugs under patent protection. Their market entry is primarily determined by the expiry of core patents and the ability to meet regulatory approval requirements.
• ANDA Filings: Taro Pharmaceuticals holds an Abbreviated New Drug Application (ANDA) for its levothyroxine sodium tablets, allowing it to market a bioequivalent generic version of the originator product [4].

Who are the Key Manufacturers and Competitors for Levothyroxine Sodium 125 mcg?

The market for levothyroxine sodium 125 mcg is highly competitive, featuring several established pharmaceutical companies vying for market share. The presence of multiple generic manufacturers intensifies price competition.

• Taro Pharmaceuticals U.S.A., Inc.: The manufacturer of NDC 00093-7629.
• Major Competitors:
  • AbbVie Inc. (and its acquired entities, e.g., Allergan): A significant player in the thyroid medication market.
  • Amneal Pharmaceuticals LLC: Offers a range of generic thyroid hormone products.
  • Mylan N.V. (now Viatris): A large generic pharmaceutical company with levothyroxine offerings.
  • Teva Pharmaceutical Industries Ltd.: Another major global generic drug manufacturer.
  • Wockhardt Limited: Competes in the generic levothyroxine market.
  • Other Generic Manufacturers: Numerous smaller and regional generic manufacturers also contribute to market supply.

Table 1: Comparative Market Presence of Key Levothyroxine Sodium Manufacturers

Manufacturer	Product Formulations Offered	Market Share (Estimated)
Taro Pharmaceuticals U.S.A., Inc.	Levothyroxine Sodium Tablets USP (125 mcg)	Moderate
AbbVie Inc.	Synthroid® (branded), Levothyroxine Sodium Tablets (generic)	High (branded), Moderate (generic)
Amneal Pharmaceuticals LLC	Levothyroxine Sodium Tablets USP	Moderate
Viatris Inc.	Levothyroxine Sodium Tablets USP	Moderate to High
Teva Pharmaceutical Industries Ltd.	Levothyroxine Sodium Tablets USP	Moderate

Note: Market share estimates are proprietary and fluctuate based on sales data. This table indicates general competitive positioning.

What are the Manufacturing Costs and Supply Chain Considerations?

The production of generic levothyroxine sodium tablets involves standard pharmaceutical manufacturing processes. Key cost drivers include API sourcing, excipient costs, manufacturing overhead, quality control, packaging, and distribution.

• API Sourcing: The active pharmaceutical ingredient (API), levothyroxine sodium, is a commodity chemical produced by several global suppliers. Price fluctuations in the API market can impact overall production costs.
• Excipients: Standard tablet excipients such as microcrystalline cellulose, lactose, and magnesium stearate are widely available and generally stable in price.
• Manufacturing Overhead: Labor, energy, and facility maintenance contribute to fixed and variable manufacturing costs. Efficiency in production lines and economies of scale are critical for cost competitiveness.
• Quality Control: Rigorous testing for purity, potency, and dissolution is essential and adds to production expenses. Adherence to Good Manufacturing Practices (GMP) is mandatory.
• Supply Chain Resilience: The global nature of API sourcing and pharmaceutical manufacturing necessitates robust supply chain management to mitigate risks from geopolitical events, natural disasters, or raw material shortages. Taro Pharmaceuticals' manufacturing locations and supplier relationships are critical factors in their cost structure and ability to meet demand.

What are the Regulatory and Pricing Influences?

The pricing of generic drugs like levothyroxine sodium is influenced by a complex interplay of regulatory policies, market dynamics, and payer negotiations.

• FDA Approval Process: Generic drugs must demonstrate bioequivalence to the reference listed drug (RLD), meaning they have the same active ingredient, dosage form, strength, and route of administration. The ANDA process requires extensive data submission and is governed by the U.S. Food and Drug Administration (FDA).
• PBMs and Rebates: Pharmacy Benefit Managers (PBMs) play a significant role in drug pricing by negotiating rebates with manufacturers on behalf of health plans. This can lead to lower net prices for PBMs and insurers, even if the list price appears higher.
• Wholesale Acquisition Cost (WAC) vs. Net Price: WAC is the list price before discounts and rebates. The actual net price paid by pharmacies and payers is significantly lower due to these negotiations.
• Generic Drug Price Erosion: Once multiple generic competitors enter the market, prices tend to decline due to intense competition. This phenomenon is well-documented for established generic drugs.
• Drug Shortage Management: While less common for highly commoditized generics like levothyroxine, periods of drug shortages can temporarily impact pricing and supply.
• Inflation Reduction Act (IRA): The IRA's provisions on drug price negotiation for Medicare could, in the future, influence pricing strategies for high-expenditure drugs, though its immediate impact on broadly available generics like levothyroxine is indirect.

What are the Price Projections for Levothyroxine Sodium 125 mcg?

Projecting the exact price for NDC 00093-7629 involves analyzing historical pricing trends, competitor activities, and market forces. Given its status as a generic product with established competition, significant price appreciation is unlikely without a disruption in supply or a major shift in market dynamics.

• Historical Trend: Generic levothyroxine sodium prices have generally followed a downward trend since the entry of multiple manufacturers. This is a characteristic of mature generic markets.
• Current Pricing Environment: Average wholesale prices (AWP) for 125 mcg levothyroxine sodium tablets can range from approximately $0.15 to $0.50 per tablet, depending on the manufacturer, pack size, and the specific contracting agreements with wholesalers and payers [5]. Net prices to PBMs and payers are substantially lower.
• Projected Trajectory:
  • Short to Medium Term (1-3 years): Continued price stability or slight erosion is anticipated. Competition among existing manufacturers will keep prices in check. Any price increases would likely be incremental, driven by modest increases in manufacturing costs or strategic supply decisions.
  • Long Term (3-5+ years): Unless new therapeutic alternatives emerge that significantly displace levothyroxine, or if manufacturing costs drastically increase due to API shortages or regulatory changes, prices are expected to remain competitive. The market will likely continue to be driven by volume and efficiency rather than significant price hikes.

Table 2: Projected Price Range for Levothyroxine Sodium 125 mcg Tablets (Per Tablet, Wholesale Acquisition Cost)

Timeframe	Projected Price Range (USD)	Factors Influencing Projection
Current	$0.15 - $0.50	Established competition, PBM negotiations, supply chain stability
1-3 Years	$0.14 - $0.48	Incremental cost inflation, continued competitive pressure
3-5+ Years	$0.13 - $0.45	Maturing generic market, potential for further efficiency gains

Note: These figures represent Wholesale Acquisition Cost (WAC) ranges and do not reflect net prices after rebates and discounts. Actual transaction prices will be lower.

Key Takeaways

• NDC 00093-7629, levothyroxine sodium 125 mcg from Taro Pharmaceuticals, is positioned within a large and growing hypothyroid treatment market.
• The active pharmaceutical ingredient is off-patent, leading to a highly competitive generic market with multiple manufacturers.
• Price projections indicate continued stability or gradual erosion due to sustained competition among generic producers.
• PBM negotiations and rebate structures significantly influence the net price paid by payers, with actual transaction costs being lower than list prices.
• Manufacturing costs are influenced by API sourcing, production efficiency, and quality control, but are generally contained due to the nature of generic drug production.

Frequently Asked Questions

1. What is the primary driver of demand for levothyroxine sodium? The primary driver is the increasing prevalence of hypothyroidism, a chronic endocrine disorder affecting millions globally.

2. How do PBMs impact the pricing of NDC 00093-7629? PBMs negotiate rebates with manufacturers, leading to lower net prices for health plans and pharmacies than the published wholesale acquisition cost.

3. Are there any upcoming patent expiries that could affect competition for this specific NDC? As this is a generic product for an off-patent API, the relevant patent landscape concerns formulation or process patents, which are generally less impactful on market entry than API patents. The market is already open to multiple generic competitors.

4. What is the typical lead time for a new generic manufacturer to enter the levothyroxine market? The lead time for a new generic manufacturer involves completing an ANDA filing, navigating the FDA review process, and establishing manufacturing and distribution channels, which can take several years.

5. Could a drug shortage for NDC 00093-7629 significantly alter its price? While a prolonged and severe drug shortage could temporarily drive up prices due to limited supply, the presence of multiple manufacturers and the mature nature of the market would likely mitigate extreme price inflation compared to a niche or single-source drug.

Citations

[1] Hage, M. P., & Azizi, F. (2014). Current status and future directions for thyroid cancer epidemiology and its control. International Journal of Preventive Medicine, 5(9), 1055–1062.

[2] Grand View Research. (2023). Thyroid Disorder Treatment Market Size, Share & Trends Analysis Report By Product (Therapy, Surgery), By Disease (Hypothyroidism, Hyperthyroidism, Thyroid Cancer), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/thyroid-disorder-treatment-market

[3] U.S. Food & Drug Administration. (2023, November 15). Thyroid disease. Retrieved from https://www.fda.gov/consumers/consumer-updates/thyroid-disease

[4] U.S. Food & Drug Administration. (n.d.). *Abbreviated New Drug Application (ANDA)​. Retrieved from https://www.fda.gov/drugs/ylmethyl-pharmaceuticals-and-your-health/abbreviated-new-drug-application-anda

[5] GoodRx. (2024). Levothyroxine prices, coupons and patient assistance programs. Retrieved from https://www.goodrx.com/levothyroxine (Note: GoodRx data provides retail price comparisons and does not directly reflect WAC or net payer prices but indicates market pricing trends.)